Insider · CIK 0001237556
Matthew W Foehr
Files at VKTX (Viking Therapeutics, Inc.), OABI (OmniAb, Inc.). First filing Dec 10, 2024, latest Apr 7, 2026.
Matthew W Foehr files SEC Form 4 as CEO, president and director at OABI (OmniAb, Inc.), and also at VKTX (Viking Therapeutics, Inc.). Since Dec 10, 2024, Matthew W Foehr has reported 0 open-market buys worth $0 and 9 open-market sells worth $1.1M, the latest filed on Apr 7, 2026.
A track record needs three past buys with six months of prices behind them; Matthew W Foehr has 0, so none is measured yet.
The newest scored trade: sold $29k of OABI on Apr 7, 2026, filed Apr 7, 2026, scored 30 (weak). In the last 12 months: 0 buys worth $0 and 5 sells worth $705k.
Where the trades landed
Last year at the 2 companies this insider has traded most, with each buy and sell on the bar it happened.
OABI: OmniAb, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
VKTX: Viking Therapeutics, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 30Weak | OmniAb, Inc. | $29k 19,244 shares | -0% | +21% from low-31% from high | |
| 32Weak | OmniAb, Inc. | $53k 30,843 shares | -1% | +37% from low-56% from high | |
| 31Weak | OmniAb, Inc. | $35k 20,754 shares | -0% | +37% from low-56% from high | |
| 39Weak | Viking Therapeutics, Inc. | $562k 16,000 shares | -11% | +77% from low-17% from high | |
| 30Weak | OmniAb, Inc. | $27k 13,666 shares | -0% | +59% from low-51% from high | |
| 31Weak | OmniAb, Inc. | $39k 19,382 shares | -1% | 0% from low-56% from high | |
| 35Weak | OmniAb, Inc. | $123k 33,486 shares | -1% | - | |
| 51Moderate | OmniAb, Inc. | $135k 41,811 shares | -1% | - | |
| 32Weak | OmniAb, Inc. | $56k 13,634 shares | -0% | - |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Apr 7, 2026 | OABI OmniAb, Inc. | 19,244 0.01% of outstanding | $29k | Apr 7, 2026 | $88k |
| Feb 17, 2026 | OABI OmniAb, Inc. | 20,483 0.01% of outstanding | $35k | Feb 17, 2026 | $27k |
| Jan 2, 2026 | VKTX VIKING THERAPEUTICS, INC. | 16,000 0.01% of outstanding | $562k | Jan 2, 2026 | none |
| Dec 8, 2025 | OABI OmniAb, Inc. | 13,666 0.01% of outstanding | $27k | Dec 8, 2025 | none |
| Apr 7, 2025 | OABI OmniAb, Inc. | 19,382 0.02% of outstanding | $39k | Apr 7, 2025 | $258k |
| Feb 18, 2025 | OABI OmniAb, Inc. | 13,964 0.01% of outstanding | $51k | Feb 18, 2025 | $192k |
| Jan 21, 2025 | OABI OmniAb, Inc. | 41,811 0.03% of outstanding | $135k | Jan 21, 2025 | $56k |
| Dec 9, 2024 | OABI OmniAb, Inc. | 13,634 0.01% of outstanding | $56k | Dec 9, 2024 | none |
Transactions
Every row this insider has filed, 43 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Apr 7, 2026 | OABI OmniAb, Inc. | MOption exercise Common Stock | +36,459 | $0.00 | $0 | 4,439,736 | Apr 7, 2026 |
| Apr 7, 2026 | OABI OmniAb, Inc. | SOpen-market sale Common Stock | -19,244 | $1.49 | $29k | 4,420,492 | Apr 7, 2026 |
| Apr 7, 2026 | OABI OmniAb, Inc. | MOption exercise Restricted Stock Unitsderivative | -36,459 | $0.00 | $0 | 309,376 | Apr 7, 2026 |
| Feb 18, 2026 | OABI OmniAb, Inc. | MOption exercise Common Stock | +58,333 | - | - | 4,434,120 | Feb 18, 2026 |
| Feb 18, 2026 | OABI OmniAb, Inc. | SOpen-market sale Common Stock | -30,843 | $1.71 | $53k | 4,403,277 | Feb 18, 2026 |
| Feb 18, 2026 | OABI OmniAb, Inc. | MOption exercise Restricted Stock Unitsderivative | -58,333 | $0.00 | $0 | 189,585 | Feb 18, 2026 |
| Feb 18, 2026 | OABI OmniAb, Inc. | AGrant or award Restricted Stock Unitsderivative | +156,250 | $0.00 | $0 | 345,835 | Feb 18, 2026 |
| Feb 18, 2026 | OABI OmniAb, Inc. | AGrant or award Stock Optionderivative | +1,562,500 | $0.00 | $0 | 1,562,500 | Feb 18, 2026 |
| Feb 16, 2026 | OABI OmniAb, Inc. | MOption exercise Common Stock | +36,458 | $0.00 | $0 | 4,396,541 | Feb 17, 2026 |
| Feb 17, 2026 | OABI OmniAb, Inc. | SOpen-market sale Common Stock | -20,754 | $1.70 | $35k | 4,375,787 | Feb 17, 2026 |
| Feb 16, 2026 | OABI OmniAb, Inc. | MOption exercise Restricted Stock Unitsderivative | -36,458 | $0.00 | $0 | 247,918 | Feb 17, 2026 |
| Jan 2, 2026 | VKTX Viking Therapeutics, Inc. | MOption exercise Common Stock, par value $0.00001 per share | +16,000 | $3.33 | $53k | 148,036 | Jan 5, 2026 |
| Jan 2, 2026 | VKTX Viking Therapeutics, Inc. | SOpen-market sale Common Stock, par value $0.00001 per share | -16,000 | $35.11 | $562k | 132,036 | Jan 5, 2026 |
| Jan 2, 2026 | VKTX Viking Therapeutics, Inc. | AGrant or award Common Stock, par value $0.00001 per share | +3,150 | $0.00 | $0 | 135,186 | Jan 5, 2026 |
| Jan 2, 2026 | VKTX Viking Therapeutics, Inc. | MOption exercise Stock Option (Right to Buy)derivative | -16,000 | $0.00 | $0 | 0 | Jan 5, 2026 |
| Jan 2, 2026 | VKTX Viking Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +20,400 | $0.00 | $0 | 20,400 | Jan 5, 2026 |
| Dec 7, 2025 | OABI OmniAb, Inc. | MOption exercise Common Stock | +26,554 | $0.00 | $0 | 4,373,749 | Dec 9, 2025 |
| Dec 8, 2025 | OABI OmniAb, Inc. | SOpen-market sale Common Stock | -13,666 | $1.96 | $27k | 4,360,083 | Dec 9, 2025 |
| Dec 7, 2025 | OABI OmniAb, Inc. | MOption exercise Restricted Stock Unitsderivative | -26,554 | $0.00 | $0 | 284,376 | Dec 9, 2025 |
| Aug 26, 2025 | OABI OmniAb, Inc. | AGrant or award Common Stock | +540,540 | $1.85 | $1000k | 4,341,987 | Aug 26, 2025 |
| Apr 11, 2025 | VKTX Viking Therapeutics, Inc. | MOption exercise Common Stock, par value $0.00001 per share | +20,786 | $8.00 | $166k | 132,036 | Apr 14, 2025 |
| Apr 11, 2025 | VKTX Viking Therapeutics, Inc. | MOption exercise Stock Option (Right to Buy)derivative | -20,786 | $0.00 | $0 | 0 | Apr 14, 2025 |
| Apr 7, 2025 | OABI OmniAb, Inc. | MOption exercise Common Stock | +36,458 | $0.00 | $0 | 3,815,618 | Apr 7, 2025 |
| Apr 7, 2025 | OABI OmniAb, Inc. | SOpen-market sale Common Stock | -19,382 | $2.00 | $39k | 3,796,236 | Apr 7, 2025 |
| Apr 7, 2025 | OABI OmniAb, Inc. | MOption exercise Restricted Stock Unitsderivative | -36,458 | $0.00 | $0 | 310,930 | Apr 7, 2025 |
| Feb 15, 2025 | OABI OmniAb, Inc. | MOption exercise Common Stock | +26,549 | - | - | 3,776,188 | Feb 19, 2025 |
| Feb 16, 2025 | OABI OmniAb, Inc. | MOption exercise Common Stock | +36,458 | - | - | 3,812,646 | Feb 19, 2025 |
| Feb 18, 2025 | OABI OmniAb, Inc. | SOpen-market sale Common Stock | -13,964 | $3.68 | $51k | 3,798,682 | Feb 19, 2025 |
| Feb 19, 2025 | OABI OmniAb, Inc. | SOpen-market sale Common Stock | -19,522 | $3.67 | $72k | 3,779,160 | Feb 19, 2025 |
| Feb 15, 2025 | OABI OmniAb, Inc. | MOption exercise Restricted Stock Unitsderivative | -26,549 | $0.00 | $0 | 208,846 | Feb 19, 2025 |
| Feb 16, 2025 | OABI OmniAb, Inc. | MOption exercise Restricted Stock Unitsderivative | -36,458 | $0.00 | $0 | 172,388 | Feb 19, 2025 |
| Feb 18, 2025 | OABI OmniAb, Inc. | AGrant or award Restricted Stock Unitsderivative | +175,000 | $0.00 | $0 | 347,388 | Feb 19, 2025 |
| Feb 18, 2025 | OABI OmniAb, Inc. | AGrant or award Stock Option (right to buy)derivative | +1,050,000 | $0.00 | $0 | 1,050,000 | Feb 19, 2025 |
| Jan 17, 2025 | OABI OmniAb, Inc. | AGrant or award Common Stock | +77,003 | $0.00 | $0 | 3,791,450 | Jan 22, 2025 |
| Jan 21, 2025 | OABI OmniAb, Inc. | SOpen-market sale Common Stock | -41,811 | $3.24 | $135k | 3,749,639 | Jan 22, 2025 |
| Jan 2, 2025 | VKTX Viking Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +18,800 | $0.00 | $0 | 18,800 | Jan 6, 2025 |
| Dec 7, 2024 | OABI OmniAb, Inc. | MOption exercise Common Stock | +26,555 | - | - | 3,728,081 | Dec 10, 2024 |
| Dec 9, 2024 | OABI OmniAb, Inc. | SOpen-market sale Common Stock | -13,634 | $4.13 | $56k | 3,714,447 | Dec 10, 2024 |
| Dec 7, 2024 | OABI OmniAb, Inc. | MOption exercise Restricted Stock Unitsderivative | -26,555 | $0.00 | $0 | 235,395 | Dec 10, 2024 |
| Nov 25, 2024 | OABI OmniAb, Inc. | MOption exercise Common Stock | +31,074 | $3.68 | $114k | 3,630,240 | Nov 26, 2024 |
| Nov 25, 2024 | OABI OmniAb, Inc. | MOption exercise Common Stock | +68,360 | $3.75 | $256k | 3,698,600 | Nov 26, 2024 |
| Nov 25, 2024 | OABI OmniAb, Inc. | MOption exercise Stock Option (right to buy)derivative | -31,074 | $0.00 | $0 | 155,371 | Nov 26, 2024 |
| Nov 25, 2024 | OABI OmniAb, Inc. | MOption exercise Stock Option (right to buy)derivative | -68,360 | $0.00 | $0 | 396,484 | Nov 26, 2024 |
Questions about Matthew W Foehr
Answered from the filings on this page, as of the latest one.
Is Matthew W Foehr buying or selling?
In the last 12 months Matthew W Foehr reported 0 open-market buys worth $0 and 5 open-market sells worth $705k on SEC Form 4; the latest was sold $29k of OABI on Apr 7, 2026. Grants, option exercises and tax withholding are not counted.
How did Matthew W Foehr's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Matthew W Foehr has 0.
Where does Matthew W Foehr file Form 4?
Matthew W Foehr has filed Form 4 at OABI (OmniAb, Inc.) as President and CEO; VKTX (Viking Therapeutics, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.